Drug & intervention

afatinib

RxCUI 1430438

Clinical trials58
Recruiting1
Related conditions20
Synonyms1

RxNorm ingredient and formulation relationships

Source-verified product relationships. Every strength, delivery form and RxCUI remains a separate clinical concept.

Loading RxNorm relationships…

Clinical trials

40 shown
Primary Tumor Resection With EGFR TKI for Stage IV NSCLCNCT05215548 · 2021-09-27
RECRUITING
A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.NCT05834348 · 2023-06-23
COMPLETED
Observational Study of Afatinib 30 mg DailyNCT04909073 · 2022-10-25
UNKNOWN
Non-interventional Study for Real-world Data of Afatinib Treatment in First-line Setting and of Subsequent Therapies for Patients With Advanced Epidermal Growth Factor Receptor (EGFR) Mutation-positive Lung AdenocarcinomaNCT04795245 · 2021-08-26
COMPLETED
FHND9041 Versus Afatinib for Non-small Cell Lung CancerNCT06759857 · 2021-08-01
ENROLLING_BY_INVITATION
Phase II Study of Afatinib Plus Bevacizumab in the Treatment Epidermal Growth Factor Receptor (EGFR) Exon G719X, S768I, and L861Q Mutation Metastatic Non-Small Cell Lung CancerNCT05267288 · 2021-02-01
UNKNOWN
Real-World Effectiveness of Afatinib (Gilotrif) Following Immunotherapy in the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: A Multi-Site Retrospective Chart Review Study in the U.S.NCT04750824 · 2020-10-15
COMPLETED
Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world StudyNCT04575415 · 2020-10-07
UNKNOWN
Neoadjuvant Afatinib Therapy for Potentially Resectable Stage III EGFR Mutation-Positive Lung AdenocarcinomaNCT04201756 · 2020-07-26
COMPLETED
The Study Observes Afatinib as First-line Treatment in Patients With Epidermal Growth Factor Receptor (EGFR) Mutation-positive Advanced Non-small Cell Lung CancerNCT04206787 · 2020-05-20
COMPLETED
A Study of HER2+ Breast Cancer Patients With Active Brain Metastases Treated With Afatinib & T-DM1 vs. T-DM1 AloneNCT04158947 · 2020-05-10
UNKNOWN
Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME TrialNCT03878524 · 2020-04-01
TERMINATED
Dry Pleurodesis With Talcum and Afatinib is Used to Treat Patients With Non-Small Cell Lung CarcinomaNCT03827070 · 2019-03-05
UNKNOWN
Afatinib and Cetuximab in Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Positive Non-small-cell Lung CancerNCT03727724 · 2018-12-04
COMPLETED
Afatinib on CNS Metastases and LMD in EGFR Mutation Positive NSCLCNCT03711422 · 2018-11-16
TERMINATED
Phase II Umbrella Study Directed by Next Generation SequencingNCT03574402 · 2018-07-09
UNKNOWN
Afatinib Plus Chemotherapy Against Esophageal or Lung Squamous Cell CarcinomaNCT03486509 · 2018-04-01
UNKNOWN
Testing Afatinib as Potentially Targeted Treatment in Cancers With EGFR Genetic Changes (MATCH - Subprotocol A)NCT06385483 · 2018-02-28
ACTIVE_NOT_RECRUITING
Afatinib Osimertinib Sequencing NISNCT03370770 · 2017-12-28
COMPLETED
Testing Afatinib in Combination With Pembrolizumab in Patients With Squamous Cell Carcinoma of the LungNCT03157089 · 2017-11-02
COMPLETED
Phase II Study of Afatinib as Third- or Further-line Treatment for Patients With Stage IV Bronchial Adenocarcinoma, Harboring Wild-type EGFR, Expressing the Neurotensin - Neurotensin Receptor ComplexNCT02876081 · 2017-09-01
WITHDRAWN
Afatinib and Necitumumab in Patients With EGFR Mutation Positive Advanced or Metastatic Non-small Cell Lung CancerNCT03054038 · 2017-07-20
TERMINATED
An Explorative Study of Afatinib in the Treatment of Advanced Cancer Carrying an EGFR, a HER2 or a HER3 MutationNCT03810872 · 2017-06-21
UNKNOWN
Deciphering Afatinib Response and Resistance With INtratumour HeterogeneityNCT02183883 · 2016-12-16
COMPLETED
Study Assessing Activity of Molecularly Matched Targeted Therapies in Select Tumor Types Based on Genomic AlterationsNCT02795156 · 2016-09-28
COMPLETED
Afatinib in Lung Cancer With EGFR Mutation From Circulating Tumor DNANCT02629523 · 2016-06-01
COMPLETED
Combination of Cetuximab With Afatinib for Patient With EGFR Mutated Lung CancerNCT02716311 · 2016-05-01
COMPLETED
Afatinib in NSCLC With HER2 MutationNCT02597946 · 2016-03-18
COMPLETED
Afatinib in EGFR+NSCLC (Recurrent or Stage IV) - Patients With Poor Performance Status (ECOG 2 or 3)NCT02695290 · 2016-03-17
TERMINATED
Evaluate the Impact of Afatinib on Quality of Life and Symptom Burden of Greek Subjects With Advanced NSCLC in Routine Patient Care SettingsNCT02440854 · 2016-02-16
COMPLETED
Neoadjuvant Afatinib in Early Stage Non Small Cell Lung Cancer.NCT02470065 · 2016-01-01
SUSPENDED
Biomarker Study Accompanying the AIO-TRK-0114 Study (MARBLE)NCT02595840 · 2015-11-25
TERMINATED
Maintaining ERBB Blockade in EGFR-mutated Lung CancerNCT02488694 · 2015-11-01
TERMINATED
Afatinib Treatment for Patients With EGFR Mutation Positive NSCLC Who Are Age 70 or OlderNCT02514174 · 2015-08-18
COMPLETED
Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial)NCT02465060 · 2015-08-17
ACTIVE_NOT_RECRUITING
Trial of Afatinib With Paclitaxel for Neoadjuvant Therapy of TNBC and Research of Biomarkers of AfatinibNCT02511847 · 2015-08-01
UNKNOWN
Afatinib and Selumetinib in Advanced KRAS Mutant and PIK3CA Wildtype Non-small Cell Lung CancerNCT02450656 · 2015-06-01
UNKNOWN
The Molecular Epidemiology of Epidermal Growth Factor Receptor (EGFR) Mutations in Patients With Advanced EGFR Mutation-positive Non-small Cell Lung Cancer Treated With AfatinibNCT04640870 · 2015-03-15
COMPLETED
Cambridge Brain Mets Trial 1NCT02768337 · 2015-03-10
TERMINATED
Xentuzumab (BI 836845) Plus Afatinib in Patients With Epidermal Growth Factor Receptor (EGFR) Mutant Non-small Cell Lung Cancer (NSCLC)NCT02191891 · 2014-10-21
COMPLETED

Conditions being studied

Carcinoma, Non-Small-Cell Lung19Non Small Cell Lung Cancer6Non-Small Cell Lung Cancer5Breast Neoplasms3EGFR Gene Mutation3Lung Cancer3Non-squamous, Non-Small Cell Lung Cancer3Refractory Malignant Solid Neoplasm3Advanced Lymphoma2Advanced Malignant Solid Neoplasm2ErbB Receptors2Lung Neoplasms2Non-small Cell Lung Carcinoma2Non-small-cell Lung Cancer With Somatic EGFR Mutations2Refractory Lymphoma2Refractory Multiple Myeloma2Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive1Advanced Breast Cancer1Advanced Lung Cancer1Anatomic Stage IV Breast Cancer AJCC v81

Leading sponsors

Boehringer Ingelheim22Guangdong Association of Clinical Trials2Massachusetts General Hospital2National Cancer Institute (NCI)2National Taiwan University Hospital2The Netherlands Cancer Institute2AIO-Studien-gGmbH1Cambridge University Hospitals NHS Foundation Trust1Center Trials & Treatment Europe1Chonnam National University Hospital1European Organisation for Research and Treatment of Cancer - EORTC1Fondation Hôpital Saint-Joseph1Fujian Cancer Hospital1GBG Forschungs GmbH1Hellenic Cooperative Oncology Group1

Drug identity and terminology: RxNorm. Trial relationships: ClinicalTrials.gov.